American Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit
Vasomune & AnGes Announce AV-001 Receives Positive Recommendation from the IDSMB
TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced today it has dosed the first patient in the Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. AV-001 is a novel pegylated peptide targeting the Tie2 receptor designed to activate the angiopoietin/Tie2 signaling pathway to normalize the vasculature.
Vasomune Therapeutics has reported preliminary positive top-line data from the Phase I clinical trial of vascular normalisation therapy in healthy volunteers.
TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced today positive top-line Phase 1 clinical trial results for AV-001, a first-in-class injectable Tie2 receptor agonist. Results from this study support the advancement of AV-001 to Phase 2a clinical studies in patients with severe COVID-19 disease. Vasomune is co-developing AV-001 with AnGes, Inc. and plans to file a Clinical Trial Application (CTA) for AV-001 with Health Canada.
TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced today positive top-line Phase 1 clinical trial results for AV-001, a first-in-class injectable Tie2 receptor agonist. Results from this study support the advancement of AV-001 to Phase 2a clinical studies in patients with severe COVID-19 disease. Vasomune is co-developing AV-001 with AnGes, Inc. and plans to file a Clinical Trial Application (CTA) for AV-001 with Health Canada.
TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for AV-001, a Tie2 tyrosine kinase receptor agonist, as a potential treatment for hospitalized patients diagnosed with moderate-to-severe COVID-19 disease.